Leave Your Message

M cutar sankarar bargo ta Lymphoblastic (T-ALL) -06

Mai haƙuri: Xiaohong

Jinsi: Namiji

Shekaru: shekara 2

Dan kasa: Sinanci

BincikeCutar sankarar bargo ta Lymphoblastic (T-ALL)

    Wani majinyacin yara mai shekaru 2 tare da T-ALL ya sami gafara bayan maganin CAR-T bayan fiye da zagaye goma na chemotherapy mai tsanani.


    Xiaohong mai shekaru biyu daga Zhejiang ya kamu da cutar sankarar bargo a lokacin bazara. Bayan fiye da shekara guda na jiyya, cytometry mai gudana ya gano koma baya, wanda ya jagoranci dangi zuwa neman maganin rigakafi na CAR-T a Asibitin Lu Daopei.


    A ranar 9 ga Agusta, 2020, an kwantar da Xiaohong a wani asibitin yara na yankin saboda "zazzabin kwanaki uku." Binciken kasusuwan kasusuwa MICM an gano cutar sankarar bargo ta lymphoblastic mai tsanani (T-ALL). Bayan wata hanya ta chemotherapy, ilimin halittar kasusuwa na kasusuwa ya nuna cikakkiyar gafara, kuma cytometry mai gudana ba a gano wasu ƙwayoyin da ba su girma ba. Ciwon daji mai tsanani na baya-bayan nan akan darussa 11 sun kiyaye cikakkiyar gafarar kasusuwa.


    A ranar 3 ga Satumba, 2021, huda bargon kasusuwa da ke biyo baya ya nuna cikakkiyar gafara a cikin ilimin halittar jiki, amma cytometry mai gudana ya bayyana 1.85% m sel marasa girma. Da yake neman ƙarin magani, an kwantar da Xiaohong a Asibitin Yanda Lu Daopei a ranar 24 ga Satumba. Lokacin da aka shigar da shi, ƙwayar kasusuwan kasusuwa har yanzu yana cikin cikakkiyar gafara, amma immunophenotyping ya nuna 0.10% m m lymphocytes T.


    Idan aka yi la'akari da shekarun Xiaohong da tsayin daka da cutar duk da sama da zagaye goma na aikin jinya, tawagar likitocin da ke shiyya ta biyu na sashen nazarin jini sun yanke shawarar cewa Xiaohong na iya shiga cikin gwajin asibiti na CD7 CAR-T.


    A ranar 30 ga Satumba, 2021, an tattara ƙwayoyin jini na gefe don al'adar tantanin halitta ta CAR-T. A ranar 10 ga Oktoba, Xiaohong ya karɓi maganin chemotherapy na FC. A ranar 13 ga Oktoba, huda bargon kashi ya nuna kasa da 5% fashewa a cikin ilimin halittar jiki, kuma cytometry kwarara ya nuna 0.37% m sel T marasa girma. A ranar 15 ga Oktoba, an sake dawo da ƙwayoyin CD7 CAR-T.


    A ranar 3 ga Janairu (kwanaki 20 bayan sake dawowa), huda kasusuwa na kasusuwa ya nuna cikakkiyar gafara a cikin ilimin halittar jiki, ba tare da wasu sel marasa girma da aka gano ta hanyar cytometry kwarara. Tun daga lokacin da yanayin Xiaohong ya daidaita, kuma an kai shi sashen dashen dashe don yin shiri don dashen kwayar halittar jini ta allogeneic.


    Xiaohong bai kai shekara daya ba lokacin da ya kamu da rashin lafiya kuma ya jure sama da shekara guda yana jinya. Nasarar haɗaɗɗen dasawa bayan CD7 CAR-T far ya samar da makami mai ƙarfi don shawo kan cutar gaba ɗaya.

    4mm3 ku

    Tun daga Yuli 2015, asibitin Lu Daopei ya fara gwajin asibiti na CAR AT a cikin cututtukan jini. A matsayin ɗaya daga cikin rukunin farko da za a fara aikin jiyya na CAR-T a China, marasa lafiya 1342 sun shiga gwajin ya zuwa yanzu, kuma bayanan asibiti sun nuna ingantaccen inganci da aminci mai iya sarrafawa. CD7 shine 40 kDa glycoprotein na dangin superfamily na immunoglobulin, kuma ana bayyana CD7 na yau da kullun akan ƙwayoyin T da ƙwayoyin NK da kuma a farkon matakan bambance-bambancen ƙwayoyin T, B da myeloid, kuma yana iya aiki azaman mai karɓar kuɗi ga hulɗar tsakanin T da B lymphocytes yayin ci gaban lymphocyte. CD7 alama ce mai tsayayye akan farfajiyar tantanin halitta ta T kuma a halin yanzu ana ƙididdige shi azaman sabon manufa tare da CAR T tantanin halitta don cutar cututtukan jini. Kwanan nan, a cikin sashe na biyu na Sashen Hematology na Asibitin Ludaopei, marasa lafiya 4 da ke da mawuyacin hali sun sami sakamako mai mahimmanci bayan jiyya na CD7 CAR-T.

    bayanin 2

    Fill out my online form.